Enliven Therapeutics, Inc.

Enliven Therapeutics believes its candidate ELVN-001 could become a second-line therapy in chronic myeloid leukemia (CML) and eventually challenge Novartis’s Scemblix in first-line use, and has just r

The capital markets continue to shy away from relatively risky investments, such as drug development, providing new funding for a limited number of companies. That means a lot of biopharmaceutical fir

Boehringer Ingelheim GmbH presented Phase Ib results and Bayer AG reported Phase I/II data for their HER2 inhibitors at World Conference on Lung Cancer (WCLC) that showed greater response rates for

Cardurion Pharmaceuticals Inc. raised $260m in series B venture capital to fund ongoing Phase II clinical trials in heart failure and a rare genetic arrhythmic disease for its two lead drug candidate